Lecca, DanielaHsueh, Shih-ChangLuo, WeimingTweedie, DavidKim, Dong SeokBaig, Abdul MannanVargesson, NeilKim, Yu KyungHwang, InhoKim, SunHoffer, Barry J.Chiang, Yung-HsiaoGreig, Nigel H2023-08-102023-08-102023-03-06Lecca, D, Hsueh, S-C, Luo, W, Tweedie, D, Kim, D S, Baig, A M, Vargesson, N, Kim, Y K, Hwang, I, Kim, S, Hoffer, B J, Chiang, Y-H & Greig, N H 2023, 'Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury', Journal of Biomedical Science, vol. 30, 16. https://doi.org/10.1186/s12929-023-00907-51423-0127ORCID: /0000-0001-8027-114X/work/145270780https://hdl.handle.net/2164/21468The authors acknowledge support from their associated institutions which included (i) the Intramural Research Program, National Institute on Aging, NIH, USA, (ii) Aevis Bio Inc., S. Korea, (iii) Aevisbio Inc., USA; (iv) Aga Khan University, Pakistan; (v) University of Aberdeen, Scotland, UK; (vi) Case Western Reserve University School of Medicine, Cleveland, USA; (vii) Taipei Medical University, Taiwan. Funding This research was supported in part by: (i) The Intramural Research Program, National Institute on Aging, National Institutes of Health, USA, (AG000994), (ii) National Institutes of Health grant R56 AG057028, USA, (iii) the Technology Development Program of MSS (S2782046) and the National Research Foundation (NRF) grant funded by the Korean government (2021M3A9G2015889), and (iv) the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program Grants, (v) the Sunny Brain Tumor and Brain Disease Research and Development Fund (106-5310-001-400), (vi) TMU-CWRU(CTSC) Pilot Program (107-3805-004-400), and (vii) the Ministry of Science and Technology, Taiwan (MOST 110-2314-B-038-106).218550347engNeuroinflammationThalidomideCereblonImmunomodulatory imide drugs 60 (IMiDs)NeurodegenerationMicrogliaTeratogenicitySpalt Like Transcription Factor (SALL4)R MedicineSupplementary DataRJournal article10.1186/s12929-023-00907-530